Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Covington
McKinsey
QuintilesIMS
Mallinckrodt
Harvard Business School
Cerilliant
US Army
Baxter

Generated: November 18, 2018

DrugPatentWatch Database Preview

Roche Palo Company Profile

« Back to Dashboard

What is the competitive landscape for ROCHE PALO, and what generic and branded alternatives to ROCHE PALO drugs are available?

ROCHE PALO has fourteen approved drugs.



Summary for Roche Palo
US Patents:0
Tradenames:7
Ingredients:9
NDAs:14
Patent Litigation for Roche Palo: See patent lawsuits for Roche Palo

Drugs and US Patents for Roche Palo

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Roche Palo TORADOL ketorolac tromethamine TABLET;ORAL 019645-001 Dec 20, 1991 DISCN Yes No ➤ Sign Up ➤ Sign Up
Roche Palo CELLCEPT mycophenolate mofetil CAPSULE;ORAL 050722-001 May 3, 1995 AB RX Yes Yes ➤ Sign Up ➤ Sign Up
Roche Palo CELLCEPT mycophenolate mofetil hydrochloride INJECTABLE;INJECTION 050758-001 Aug 12, 1998 AP RX Yes Yes ➤ Sign Up ➤ Sign Up
Roche Palo CYTOVENE ganciclovir CAPSULE;ORAL 020460-001 Dec 22, 1994 DISCN Yes No ➤ Sign Up ➤ Sign Up
Roche Palo CYTOVENE ganciclovir sodium INJECTABLE;INJECTION 019661-001 Jun 23, 1989 AP RX Yes Yes ➤ Sign Up ➤ Sign Up
Roche Palo TORADOL ketorolac tromethamine INJECTABLE;INJECTION 019698-002 Nov 30, 1989 DISCN Yes No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Roche Palo

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Roche Palo CYTOVENE ganciclovir CAPSULE;ORAL 020460-002 Dec 12, 1997 4,355,032 ➤ Sign Up
Roche Palo TICLID ticlopidine hydrochloride TABLET;ORAL 019979-002 Oct 31, 1991 4,591,592 ➤ Sign Up
Roche Palo CELLCEPT mycophenolate mofetil SUSPENSION;ORAL 050759-001 Oct 1, 1998 5,688,529 ➤ Sign Up
Roche Palo AEROBID flunisolide AEROSOL, METERED;INHALATION 018340-001 Aug 17, 1984 4,933,168 ➤ Sign Up
Roche Palo TICLID ticlopidine hydrochloride TABLET;ORAL 019979-002 Oct 31, 1991 4,051,141 ➤ Sign Up
Roche Palo CYTOVENE ganciclovir CAPSULE;ORAL 020460-001 Dec 22, 1994 4,423,050 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for ROCHE PALO drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe For Oral Suspension 200 mg/mL ➤ Subscribe 2011-03-25
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Julphar
Daiichi Sankyo
Citi
Chubb
Cipla
Argus Health
US Army
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.